Vyant Bio, Inc.
VYNTDelisted May 4, 2023- Industry
- Services-Medical Laboratories
- SEC CIK
- 0001349929
Vyant Bio, Inc. was delisted on May 4, 2023; its insiders filed their last Form 4 on Feb 27, 2023; 17 institutions reported holding it in 13F filings for Q1 2023, worth $136.8K in total; no superinvestor held it.
13F holders, Q3 2023
Institutional positions in Vyant Bio, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
VYNT is no longer listed, and 13F filings after Q1 2023 list far fewer holders. See Q1 2023
- Institutional holders
- 0
- −1 vs. Q2 2023
- Shares held
- 0
- −3 (−100.0%) vs. Q2 2023
- Total value
- $0
- −$1 (−100.0%) vs. Q2 2023
- New holders
- 0
- 0 more added
- Sold out
- 1
- 0 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VYNT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 1 | $1 |
| Q1 2023 | 17 | $136.8K |
| Q4 2022 | 17 | $222.1K |
| Q3 2022 | 26 | $949.3K |
| Q2 2022 | 21 | $1.47M |
| Q1 2022 | 23 | $2.54M |
| Q4 2021 | 27 | $3.12M |
| Q3 2021 | 23 | $5.27M |
| Q2 2021 | 29 | $8.41M |
| Q1 2021 | 18 | $2.96M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Vyant Bio, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Barclays PLC | 0 | $0 | 0.00% | −3−100.0% | Sold out |